Table of Contents
Letter to the Editor
Journal of Allergy
Volume 2012, Article ID 381737, 9 pages
http://dx.doi.org/10.1155/2012/381737
Review Article

Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review

1Research Center for Allergy and Immunology, Yokohama Institute, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
2Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohara, Chuo-ku, Chiba 260-8670, Japan

Received 22 July 2011; Accepted 15 November 2011

Academic Editor: Nerin N. Bahceciler

Copyright © 2012 Takashi Fujimura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Jáuregui, J. Mullol, I. Dávila et al., “Allergic rhinitis and school performance,” Journal of Investigational Allergology and Clinical Immunology, vol. 19, supplement 1, pp. 32–39, 2009. View at Google Scholar
  2. S. Walker, S. Khan-Wasti, M. Fletcher, P. Cullinan, J. Harris, and A. Sheikh, “Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study,” Journal of Allergy and Clinical Immunology, vol. 120, no. 2, pp. 381–387, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. L. Noon, “Prophylactic inoculation against hay fever,” The Lancet, vol. 177, no. 4580, pp. 1572–1573, 1911. View at Google Scholar · View at Scopus
  4. M. Larché, C. A. Akdis, and R. Valenta, “Immunological mechanisms of allergen-specific immunotherapy,” Nature Reviews Immunology, vol. 6, no. 10, pp. 761–771, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. P. L. Bhalla and M. B. Singh, “Biotechnology-based allergy diagnosis and vaccination,” Trends in Biotechnology, vol. 26, no. 3, pp. 153–161, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. U. Müller, Y. Hari, and E. Berchtold, “Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 107, no. 1, pp. 81–86, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. Kuehr, J. Brauburger, S. Zielen et al., “Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis,” Journal of Allergy and Clinical Immunology, vol. 109, no. 2, pp. 274–280, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Klunker, L. R. Saggar, V. Seyfert-Margolis et al., “Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding,” Journal of Allergy and Clinical Immunology, vol. 120, no. 3, pp. 688–695, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. G. W. Canonica and G. Passalacqua, “Noninjection routes for immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 111, no. 3, pp. 437–448, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Senti, B. M. Prinz Vavricka, I. Erdmann et al., “Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 46, pp. 17908–17912, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. C. Incorvaia, S. Masieri, S. Scurati, S. Soffia, P. Puccinelli, and F. Frati, “The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children,” Journal of Asthma and Allergy, no. 4, pp. 13–17, 2011. View at Publisher · View at Google Scholar · View at PubMed
  12. A. Antico, M. Pagani, and A. Crema, “Anaphylaxis by latex sublingual immunotherapy,” Allergy, vol. 61, no. 10, pp. 1236–1237, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. E. H. Dunsky, M. F. Goldstein, D. J. Dvorin, and G. A. Belecanech, “Anaphylaxis to sublingual immunotherapy,” Allergy, vol. 61, no. 10, p. 1235, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. A. O. Eifan, S. Keles, N. N. Bahceciler, and I. B. Barlan, “Anaphylaxis to multiple pollen allergen sublingual immunotherapy,” Allergy, vol. 62, no. 5, pp. 567–568, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. H. De Groot and A. Bijl, “Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet,” Allergy, vol. 64, no. 6, pp. 963–964, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. M. Cochard and P. A. Eigenmann, “Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 124, no. 2, pp. 378–379, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. L. Blazowski, “Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose,” Allergy, vol. 63, no. 3, p. 374, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. S. Radulovic, D. Wilson, M. Calderon, and S. Durham, “Systematic reviews of sublingual immunotherapy (SLIT),” Allergy, vol. 66, no. 6, pp. 740–752, 2011. View at Publisher · View at Google Scholar · View at PubMed
  19. L. Cox, J. T. Li, and H. Nelson, “Allergen immunotherapy: a practice parameter second update,” Journal of Allergy and Clinical Immunology, vol. 120, supplement 3, pp. S25–S85, 2007. View at Publisher · View at Google Scholar · View at PubMed
  20. T. H. Larsen, L. K. Poulsen, M. Melac, A. Combebias, C. Andre, and H. J. Malling, “Safety and tolerability of grass pollen tablets in sublingual immunotherapy—a phase-1 study,” Allergy, vol. 61, no. 10, pp. 1173–1176, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. D. Passali, R. Mösges, G. C. Passali, F. M. Passali, G. Ayoko, and L. Bellussi, “Safety, tolerability and efficacy of sublingual allergoid immunotherapy with three different shortened up-dosing administration schedules,” Acta Otorhinolaryngologica Italica, vol. 30, no. 3, pp. 131–137, 2010. View at Google Scholar · View at Scopus
  22. I. Stelmach, J. Kaczmarek-Woźniak, P. Majak, M. Olszowiec-Chlebna, and J. Jerzynska, “Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen,” Clinical and Experimental Allergy, vol. 39, no. 3, pp. 401–408, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. Seidenberg, G. B. Pajno, C. P. Bauer, S. La Grutta, and J. Sieber, “Safety and tolerability of seasonal ultra-rush, high-dose sublingual- swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents,” Journal of Investigational Allergology and Clinical Immunology, vol. 19, no. 2, pp. 125–131, 2009. View at Google Scholar · View at Scopus
  24. R. E. Rossi, G. Monasterolo, G. Coco, and D. Operti, “Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis,” International Archives of Allergy and Immunology, vol. 138, no. 2, pp. 105–110, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. F. Rodriguez, M. Boquete, M. D. Ibáñez, F. De La Torre-Martínez, and A. I. Tabar, “Once daily sublingual immunotherapy without updosing—a new treatment schedule,” International Archives of Allergy and Immunology, vol. 140, no. 4, pp. 321–326, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. D. Di Bona, A. Plaia, V. Scafidi, M. S. Leto-Barone, and G. Di Lorenzo, “Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis,” Journal of Allergy and Clinical Immunology, vol. 126, no. 3, pp. 558–566, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. M. S. Khinchi, L. K. Poulsen, F. Carat, C. André, A. B. Hansen, and H. J. Malling, “Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study,” Allergy, vol. 59, no. 1, pp. 45–53, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. R. Durham, “Sublingual immunotherapy: What have we learnt from the 'big trials'?” Current Opinion in Allergy and Clinical Immunology, vol. 8, no. 6, pp. 577–584, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. M. T. Ventura, A. Carretta, R. A. Tummolo, R. Buquicchio, A. Arsieni, and N. Murgia, “Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 2, pp. 403–413, 2009. View at Google Scholar · View at Scopus
  30. S. Keles, E. Karakoc-Aydiner, A. Ozen et al., “A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes,” Journal of Allergy and Clinical Immunology, vol. 128, no. 4, pp. 808–815.e7, 2011. View at Publisher · View at Google Scholar · View at PubMed
  31. P. Panzner, M. Petráš, T. Sýkora, I. K. Lesná, and M. Liška, “Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy,” Allergy and Asthma Proceedings, vol. 32, no. 2, pp. 142–150, 2011. View at Publisher · View at Google Scholar · View at PubMed
  32. F. Marcucci, L. Sensi, G. Di Cara et al., “Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy,” Pediatric Allergy and Immunology, vol. 16, no. 6, pp. 519–526, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. R. Tahamiler, G. Saritzali, and S. Canakcioglu, “Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis,” Laryngoscope, vol. 117, no. 6, pp. 965–969, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. H. Ott, J. Sieber, R. Brehler et al., “Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study,” Allergy, vol. 64, no. 1, pp. 179–186, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. L. Frølund, S. R. Durham, M. Calderon et al., “Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life,” Allergy, vol. 65, no. 6, pp. 753–757, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. T. Fujimura, S. Yonekura, S. Horiguchi et al., “Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis,” Clinical Immunology, vol. 139, no. 1, pp. 65–74, 2011. View at Publisher · View at Google Scholar · View at PubMed
  37. S. R. Durham, W. Emminger, A. Kapp et al., “Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet,” Journal of Allergy and Clinical Immunology, vol. 125, no. 1–3, pp. 131–138.e7, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. M. Marogna, I. Spadolini, A. Massolo, G. W. Canonica, and G. Passalacqua, “Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study,” Journal of Allergy and Clinical Immunology, vol. 126, no. 5, pp. 969–975, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. C. Incorvaia, A. Rapetti, S. Scurati, P. Puccinelli, M. Capecce, and F. Frati, “Importance of patient's education in favouring compliance with sublingual immunotherapy,” Allergy, vol. 65, no. 10, pp. 1341–1342, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. C. Incorvaia, S. Masieri, P. Berto, S. Scurati, and F. Frati, “Specific immunotherapy by the sublingual route for respiratory allergy,” Allergy, Asthma & Clinical Immunology, vol. 6, article 29, 2010. View at Google Scholar
  41. A. Jansen, K. F. Andersen, and H. Brüning, “Evaluation of a compliance device in a subgroup of adult patients receiving specific immunotherapy with grass allergen tablets (GRAZAX®) in a randomized, open-label, controlled study: An a priori subgroup analysis,” Clinical Therapeutics, vol. 31, no. 2, pp. 321–327, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. K. W. Kim, E. A. Kim, B. C. Kwon et al., “Comparison of allergic indices in monosensitized and polysensitized patients with childhood asthma,” Journal of Korean Medical Science, vol. 21, no. 6, pp. 1012–1016, 2006. View at Google Scholar · View at Scopus
  43. G. Ciprandi, G. Cadario, C. Valle et al., “Sublingual immunotherapy in polysensitized patients: effect on quality of life,” Journal of Investigational Allergology and Clinical Immunology, vol. 20, no. 4, pp. 274–279, 2010. View at Google Scholar · View at Scopus
  44. G. Ciprandi, C. Incorvaia, P. Puccinelli, S. Soffia, S. Scurati, and F. Frati, “Polysensitization as a challenge for the allergist: the suggestions provided by the Polysensitization Impact on Allergen Immunotherapy studies,” Expert Opinion on Biological Therapy, vol. 11, no. 6, pp. 715–722, 2011. View at Publisher · View at Google Scholar · View at PubMed
  45. S. M. Amar, R. J. Harbeck, M. Sills, L. J. Silveira, H. O'Brien, and H. S. Nelson, “Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract,” Journal of Allergy and Clinical Immunology, vol. 124, no. 1, pp. 150–156.e5, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. F. Purello-D'Ambrosio, S. Gangemi, R. A. Merendino et al., “Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study,” Clinical and Experimental Allergy, vol. 31, no. 8, pp. 1295–1302, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Marogna, D. Tomassetti, A. Bernasconi et al., “Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study,” Annals of Allergy, Asthma and Immunology, vol. 101, no. 2, pp. 206–211, 2008. View at Google Scholar · View at Scopus
  48. T. Kinaciyan, B. Jahn-Schmid, A. Radakovics et al., “Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1,” Journal of Allergy and Clinical Immunology, vol. 119, no. 4, pp. 937–943, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. L. Cox, D. Larenas-Linnemann, R. F. Lockey, and G. Passalacqua, “Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System,” Journal of Allergy and Clinical Immunology, vol. 125, no. 3, pp. 569–574e7, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. L. S. Cox, D. L. Linnemann, H. Nolte, D. Weldon, I. Finegold, and H. S. Nelson, “Sublingual immunotherapy: a comprehensive review,” Journal of Allergy and Clinical Immunology, vol. 117, no. 5, pp. 1021–1035, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. S. R. Durham, A. O. Birk, and J. S. Andersen, “Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials,” Allergy, vol. 66, no. 1, pp. 120–123, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. J. B. Sun, N. Cuburu, M. Blomquist, B. L. Li, C. Czerkinsky, and J. Holmgren, “Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions,” Scandinavian Journal of Immunology, vol. 64, no. 3, pp. 251–259, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. L. Van Overtvelt, V. Lombardi, A. Razafindratsita et al., “IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model,” International Archives of Allergy and Immunology, vol. 145, no. 2, pp. 152–162, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. L. Van Overtvelt, H. Moussu, S. Horiot et al., “Lactic acid bacteria as adjuvants for sublingual allergy vaccines,” Vaccine, vol. 28, no. 17, pp. 2986–2992, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. A. Razafindratsita, N. Saint-Lu, L. Mascarell et al., “Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation,” Journal of Allergy and Clinical Immunology, vol. 120, no. 2, pp. 278–285, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. O. Pfaar, C. Barth, C. Jaschke, K. Hörmann, and L. Klimek, “Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study,” International Archives of Allergy and Immunology, vol. 154, no. 4, pp. 336–344, 2011. View at Publisher · View at Google Scholar · View at PubMed
  57. T. Fujimura and Y. Okamoto, “Antigen-specific immunotherapy against allergic rhinitis: the state of the art,” Allergology International, vol. 59, no. 1, pp. 21–31, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. M. Jutel and C. A. Akdis, “Immunological mechanisms of allergen-specific immunotherapy,” Allergy, vol. 66, no. 6, pp. 725–732, 2011. View at Publisher · View at Google Scholar · View at PubMed
  59. G. Ciprandi, D. Fenoglio, I. Cirillo et al., “Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report,” Annals of Allergy, Asthma and Immunology, vol. 95, no. 1, pp. 38–44, 2005. View at Google Scholar · View at Scopus
  60. G. Ciprandi, I. Cirillo, D. Fenoglio, G. Marseglia, and M. A. Tosca, “Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports,” International Immunopharmacology, vol. 6, no. 8, pp. 1370–1373, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. B. Bohle, T. Kinaciyan, M. Gerstmayr, A. Radakovics, B. Jahn-Schmid, and C. Ebner, “Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation,” Journal of Allergy and Clinical Immunology, vol. 120, no. 3, pp. 707–713, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. T. Fujimura, S. Yonekura, Y. Taniguchi et al., “The induced regulatory T cell level, defined as the proportion of IL-10+Foxp3+ cells among CD25+CD4+ leukocytes, is a potential therapeutic biomarker for sublingual immunotherapy: a preliminary report,” International Archives of Allergy and Immunology, vol. 153, no. 4, pp. 378–387, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. G. Di Lorenzo, P. Mansueto, M. L. Pacor et al., “Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1103–1110.e4, 2009. View at Publisher · View at Google Scholar · View at PubMed
  64. N. Novak, T. Bieber, and J.-P. Allam, “Immunological mechanisms of sublingual allergen-specific immunotherapy,” Allergy, vol. 66, no. 6, pp. 733–739, 2011. View at Publisher · View at Google Scholar · View at PubMed
  65. S. Piconi, D. Trabattoni, V. Rainone et al., “Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4,” Journal of Immunology, vol. 185, no. 12, pp. 7723–7730, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. L. Wang, K. Pino-Lagos, V. C. De Vries, I. Guleria, M. H. Sayegh, and R. J. Noelle, “Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 27, pp. 9331–9336, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. L. M. Francisco, V. H. Salinas, K. E. Brown et al., “PD-L1 regulates the development, maintenance, and function of induced regulatory T cells,” Journal of Experimental Medicine, vol. 206, no. 13, pp. 3015–3029, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. P. Van Den Elzen, S. Garg, L. León et al., “Apolipoprotein-mediated pathways of lipid antigen presentation,” Nature, vol. 437, no. 7060, pp. 906–910, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. C. Tenger and X. Zhou, “Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell,” Immunology, vol. 109, no. 3, pp. 392–397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Makino, E. Noguchi, N. Takahashi et al., “Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis,” Journal of Allergy and Clinical Immunology, vol. 126, no. 6, pp. 1163–1169.e1, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. T. Akkoc, M. Akdis, and C. A. Akdis, “Update in the mechanisms of allergen-specific immunotheraphy,” Allergy, Asthma and Immunology Research, vol. 3, no. 1, pp. 11–20, 2010. View at Publisher · View at Google Scholar · View at PubMed
  72. L. Mascarell, V. Lombardi, A. Louise et al., “Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells,” Journal of Allergy and Clinical Immunology, vol. 122, no. 3, pp. 603–609.e5, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. J. P. Allam, N. Novak, C. Fuchs et al., “Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcεRI expression,” Journal of Allergy and Clinical Immunology, vol. 112, no. 1, pp. 141–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. J. P. Allam, W. M. Peng, T. Appel et al., “Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells,” Journal of Allergy and Clinical Immunology, vol. 121, no. 2, pp. 368–374.e1, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. J. P. Allam, P. A. Würtzen, M. Reinartz et al., “Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-β1 and IL-10-producing properties,” Journal of Allergy and Clinical Immunology, vol. 126, no. 3, pp. 638–645.e1, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. M. Larché, “Immune mechanisms of sublingual immunotherapy: are oral Langerhans cells the masters of tolerance?” Journal of Allergy and Clinical Immunology, vol. 126, no. 3, pp. 646–647, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. P. A. Wachholz and S. R. Durham, “Induction of 'blocking' IgG antibodies during immunotherapy,” Clinical and Experimental Allergy, vol. 33, no. 9, pp. 1171–1174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Akdis and C. A. Akdis, “Mechanisms of allergen-specific immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 119, no. 4, pp. 780–789, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. F. L. Van der Heijden, R. J. Joost van Neerven, M. Van Katwijk, J. D. Bos, and M. L. Kapsenberg, “Serum-IgE-facilitated allergen presentation in atopic disease,” Journal of Immunology, vol. 150, no. 8, pp. 3643–3650, 1993. View at Google Scholar · View at Scopus
  80. S. Palaniyandi, E. Tomei, Z. Li, D. H. Conrad, and X. Zhu, “CD23-dependent transcytosis of IgE and immune complex across the polarized human respiratory epithelial cells,” Journal of Immunology, vol. 186, no. 6, pp. 3484–3496, 2011. View at Publisher · View at Google Scholar · View at PubMed
  81. G. W. Scadding, M. H. Shamji, M. R. Jacobson et al., “Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells,” Clinical and Experimental Allergy, vol. 40, no. 4, pp. 598–606, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. P. A. Würtzen, G. Lund, K. Lund, M. Arvidsson, S. Rak, and H. Ipsen, “A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation,” Clinical and Experimental Allergy, vol. 38, no. 8, pp. 1290–1301, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. I. Pree, M. H. Shamji, I. Kimber, R. Valenta, S. R. Durham, and V. Niederberger, “Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules,” Clinical and Experimental Allergy, vol. 40, no. 9, pp. 1346–1352, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. R. J. J. Van Neerven, M. Arvidssont, H. Ipsen, S. H. Sparholt, S. Rak, and P. A. Würtzen, “A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation,” Clinical and Experimental Allergy, vol. 34, no. 3, pp. 420–428, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. R. J. J. Van Neerven, T. Wikborg, G. Lund et al., “Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation,” Journal of Immunology, vol. 163, no. 5, pp. 2944–2952, 1999. View at Google Scholar · View at Scopus
  86. L. K. James, M. H. Shamji, S. M. Walker et al., “Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies,” Journal of Allergy and Clinical Immunology, vol. 127, no. 2, pp. 509–516.e5, 2011. View at Publisher · View at Google Scholar · View at PubMed